XML 31 R13.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Stock-Based Compensation [Abstract] |
Stock-Based Compensation | Note 6. Stock-Based Compensation The Company’s 2015 Stock Award and Incentive Plan provides for grants of incentive and non-qualified stock options, restricted stock, stock appreciation rights, stock awards and performance unit awards (the 2015 Stock Award and Incentive Plan, as amended, referred to herein as the “Plan” and together with its predecessor for awards granted prior to May 2015, the 2001 Stock Award and Incentive Plan, as amended and restated, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. Stock options granted under the Plans generally have a ten year term. The exercise price for stock options are at prices at or above the fair market value of the common stock on the date of the grant, and each award of stock options will vest ratably over a specified period, generally three years. Stock-based compensation expense is recognized in the consolidated financial statements for stock options based on the grant date fair value. Net income for years ended 2021, 2020 and 2019 include $4.9 million, $4.6 million and $4.8 million pre-tax compensation costs, respectively, related to stock option expense as a component of marketing and administrative expenses. All stock option expense is recognized in the consolidated statements of operations. The related tax benefit included in the statement of income on the non-qualified stock options was $1.3 million, $1.2 million and $1.3 million for 2021, 2020 and 2019, respectively. Stock Options The fair value of options granted is estimated on the date of grant using the Black-Scholes valuation model. Compensation expense is recognized only for those options expected to vest, with forfeitures estimated at the date of grant based on the Company's historical experience and future expectations. The forfeiture rate assumption used for the periods ended December 31, 2021, 2020 and 2019 was 8.38%, 8.45% and 8.85%, respectively. The weighted average grant date fair value for stock options granted during the years ended December 31, 2021, 2020 and 2019 was $21.62, $18.99 and $18.86, respectively. The weighted average grant date fair value for stock options vested during 2021, 2020 and 2019 was $20.56, $23.85 and $22.46, respectively. The total intrinsic value of stock options exercised during the years ended December 31, 2021, 2020 and 2019 was $6.1 million, $2.3 million and $2.2 million, respectively. The fair value for stock awards was estimated at the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions for the years ended December 31, 2021, 2020 and 2019:
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Expected life (in years) |  |  | 6.9 |  |  |  | 6.7 |  |  |  | 6.6 |
Interest rate |  |  | 0.71 | % |  |  | 1.67 | % |  |  | 2.62 | %
Volatility |  |  | 32.04 | % |  |  | 30.34 | % |  |  | 30.26 | %
Expected dividend yield |  |  | 0.31 | % |  |  | 0.35 | % |  |  | 0.37 | %
The expected term of the options represents the estimated period of time until exercised and is based on historical experience of similar awards, based upon contractual terms, vesting schedules, and expectations of future employee behavior. The expected stock-price volatility is based upon the historical and implied volatility of the Company's stock. The interest rate is based upon the implied yield on U.S. Treasury bills with an equivalent remaining term. Estimated dividend yield is based upon historical dividends paid by the Company. The following table summarizes stock option activity for the year ended December 31, 2021:
|  | Awards |  |  | Weighted Average Exercise Price per Share |  | Weighted Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value (Millions) |
Awards outstanding at December 31, 2020 |  |  | 1,363,366 |  |  | $ | 57.29 |  |  |  |  |
Granted |  |  | 255,769 |  |  |  | 66.00 |  |  |  |  |
Exercised |  |  | (251,195 | ) |  |  | 51.12 |  |  |  |  |
Canceled |  |  | (37,938 | ) |  |  | 64.92 |  |  |  |  |  |  |
Awards outstanding at December 31, 2021 |  |  | 1,330,002 |  |  | $ | 59.91 |  |  |  | 6.14 |  |  | $ | 18.7 |
Awards exercisable at December 31, 2021 |  |  | 834,060 |  |  | $ | 59.09 |  |  |  | 4.80 |  |  | $ | 12.8 |
The aggregate intrinsic value above is calculated before applicable income taxes, based on the Company's closing stock price of $73.15 as of the last business day of the period ended December 31, 2021 had all options been exercised on that date. The weighted average intrinsic value of the options exercised during 2021, 2020 and 2019 was $24.43, $24.41 and $27.21 per share, respectively. As of December 31, 2021, total unrecognized stock-based compensation expense related to non-vested stock options was approximately $4.9 million, which is expected to be recognized over a weighted average period of approximately three years. The Company issues new shares of common stock upon the exercise of stock options. Non-vested stock option activity for the year ended December 31, 2021 is as follows:
|  | Awards |  |  | Weighted Average Grant Date Fair Value per Share |
Nonvested awards outstanding at December 31, 2020 |  |  | 487,160 |  |  | $ | 58.61 |
Granted |  |  | 255,769 |  |  |  | 66.00 |
Vested |  |  | (225,402 | ) |  |  | 60.88 |
Canceled |  |  | (21,585 | ) |  |  | 61.11 |
Nonvested awards outstanding at December 31, 2021 |  |  | 495,942 |  |  | $ | 61.28 |
Restricted Stock The Company has granted key employees rights to receive shares of the Company's common stock pursuant to the Plan. The rights will be deferred for a specified number of years of service, subject to restrictions on transfer and other conditions. Compensation expense for these shares is recognized over the vesting period. The Company granted 102,309 shares, 108,212 shares and 116,901 shares for the periods ended December 31, 2021, 2020 and 2019, respectively. The fair value was determined based on the market value of unrestricted shares. As of December 31, 2021, there was unrecognized stock-based compensation related to restricted stock of $6.4 million, which will be recognized over approximately the next three years. The compensation expense amortized with respect to all units was approximately $5.9 million, $5.6 million and $5.2 million for the periods ended December 31, 2021, 2020 and 2019, respectively. In addition, the Company recorded reversals of $2.6 million, $2.3 million and $1.9 million for periods ended December 31, 2021, 2020 and 2019, respectively, related mostly to the conversion of restricted stock for tax withholding purposes. Such costs and reversals are included in marketing and administrative expenses. The following table summarizes the restricted stock activity for the Plan:
|  | Awards |  |  | Weighted Average Grant Date Fair Value per Share |
Unvested balance at December 31, 2020 |  |  | 201,985 |  |  | $ | 58.07 |
Granted |  |  | 102,309 |  |  |  | 66.20 |
Vested |  |  | (51,497 | ) |  |  | 60.40 |
Canceled |  |  | (56,664 | ) |  |  | 60.98 |
Unvested balance at December 31, 2021 |  |  | 196,133 |  |  | $ | 60.87 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration